查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992475

獸藥市場：2026年至2032年全球市場預測（依藥物類型、目標動物、劑型、給藥途徑、製劑類型、通路、治療領域及最終用戶分類）

Animal Drug Compounding Market by Drug Type, Animal Type, Form, Route Of Administration, Compounding Type, Distribution Channel, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物藥品市場價值將達到 14.5 億美元，到 2026 年將成長到 15.7 億美元，到 2032 年將達到 25.1 億美元，複合年成長率為 8.10%。

主要市場統計數據
基準年 2025 14.5億美元
預計年份：2026年 15.7億美元
預測年份 2032 25.1億美元
複合年成長率 (%) 8.10%

關於動物製劑在獸醫和農業健康中的戰略作用、範圍和實際目標的權威框架。

本執行摘要首先概述了動物製劑在現代獸醫學和農業管理中的戰略必要性。製劑的出現拓展了獸醫和動物保健專業人員的治療選擇，使其能夠實現劑量客製化、為小型或易感動物提供替代配方，以及在核准的產品缺貨時提供定製配方。因此，製劑有助於改善急性和慢性疾病的臨床療效，提高伴侶動物的用藥依從性，並為特殊畜牧業的干涉措施提供針對性解決方案。

監管力道加大、供應鏈波動以及臨床上對個人化治療方法的需求，是如何改變藥品分發操作和品管系統的？

近年來，動物用藥品產業經歷了與監管、臨床實踐和供應鏈趨勢相關的多項變革性變化。法律規範提高了全球對無菌性、標籤和批號記錄的標準，迫使藥劑師加強品質系統建設並增加對環境監測項目的投入。同時，臨床實踐也在不斷發展，獸醫越來越依賴定製配方來應對諸如慢性病管理、老年動物護理以及市售產品無法滿足的物種特異性劑量等挑戰。

2025 年美國關稅調整對整個藥局業務的採購、配方驗證和定價趨勢的營運和採購影響。

2025年美國實施或調整的關稅政策和貿易措施對藥房生態系統產生了重大營運影響，尤其對活性成分、添加劑、包裝材料和專用設備的進口影響顯著。某些化學品和成品關稅的增加往往會對全球採購的原料造成成本壓力，促使採購團隊重新評估其供應商組合和總到岸成本。對於規模小規模、難以承受原料價格劇烈波動的藥局和診所而言，這些影響更為顯著。

一個詳細的細分框架，將藥物類別、特異性疾病需求、製劑類型、給藥途徑、分銷管道和最終用戶概況與營運重點聯繫起來。

透過詳細的細分觀點，可以揭示臨床需求、製劑能力和分銷管道的重疊領域，從而突出目標機會和營運挑戰。根據藥物類型，分銷需求涵蓋抗感染藥物、抗發炎藥物、中樞神經系統 (CNS) 藥物、荷爾蒙及其替代品，每種藥物在穩定性、輔料和無菌性方面都有其獨特的考量。例如，荷爾蒙製劑需要特殊的處理和低溫運輸要求，而中樞神經系統藥物通常需要精確的劑量調整和對副作用的密切監測。

美洲、歐洲、中東和非洲以及亞太地區的區域監管差異、供應鏈角色和實施模式如何影響分銷策略和營運風險？

區域趨勢持續影響整個製藥業的監管預期、籌資策略和應用模式。在美洲，法律規範強調可追溯性、無菌保證和配藥記錄的透明度，而商業性應用則受到服務於伴侶動物和大規模畜牧養殖場的獸醫院和專科藥房組成的密集生態系統的影響。這種區域結構既有利於快速的臨床回饋循環，也有利於集中監管配藥操作和文件記錄。

藥局供應商的策略重點和營運差異化因素，重點在於優質基礎設施、臨床整合和有韌性的供應鏈。

動物用藥品分送產業的企業正著力應對多項策略挑戰，這些挑戰決定了它們的績效和韌性。領先的藥房和服務供應商優先投資於高品質的基礎設施，包括經過驗證的無塵室、環境監測系統和嚴格的無菌檢測通訊協定，以滿足日益成長的監管要求，並拓展注射劑和生物製藥等相關製劑的業務。除了設施升級外，各企業還在透過標準化批次記錄、電子追溯和定期第三方審核來制定合規計畫。

醫藥產業的領導者們正在採取切實有效且影響深遠的營運、採購、臨床合作和品質舉措，以提高安全性和業務永續營運。

產業領導者應採取一系列切實有效的措施，以確保病患安全、符合監管要求，並保障藥品分發營運整體的業務永續營運。首先，應優先投資於符合現行藥典要求的已驗證無菌製程和環境監測。這將降低注射劑製劑的風險，並支持臨床給藥的擴展。其次，應實施全面的供應商合格通訊協定，包括關鍵原料藥（活性成分）的雙源策略和定期供應商審核，以降低關稅和供應鏈波動帶來的風險。

我們採用高度透明的混合方法，結合與從業人員的訪談、實地評估、監管審查和資料檢驗，確保提供切實可行且檢驗的見解。

本報告的研究採用混合方法，以確保對藥品分發實踐、法規環境和終端用戶行為獲得全面且檢驗的見解。主要研究包括對執業獸醫、配藥藥劑師、品質保證負責人和供應鏈經理進行結構化訪談，以了解實際限制和臨床優先事項。此外，現場評估和流程觀察直接揭示了設施佈局、無菌控制和文件記錄實踐。

整合策略挑戰，強調品質、臨床協作、採購韌性和以社區為基礎的永續配藥運作方法。

本執行摘要了動物用藥品製劑領域的核心挑戰：維持嚴格的品質體系，根據物種和治療方法需求調整製劑能力，以及建構能夠應對關稅和物流中斷的彈性供應鏈。擴大安全注射劑和複雜製劑的範圍需要完善的滅菌和文件記錄流程。同時，與獸醫和終端使用者進行臨床合作和回饋機制對於實現治療效果和提高用藥依從性仍然至關重要，尤其是在偏好和給藥方式都面臨挑戰的伴侶動物領域。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：獸藥市場（依藥物類型分類）

  • 抗感染藥物
  • 抗發炎藥
  • 中樞神經系統藥物
  • 荷爾蒙及其替代品

第9章：獸藥市場：依動物類型分類

  • 伴侶動物
    • 貓
    • 狗
    • 馬
  • 家畜
    • 牛
    • 家禽
    • 綿羊/山羊
    • 豬

第10章：獸藥市場：依劑型分類

  • 膠囊
  • 解決方案
  • 懸浮液

第11章：獸藥市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用

第12章：獸藥市場（依藥品類型分類）

  • 非無菌配製
  • 無菌配製

第13章：獸藥市場：依通路分類

  • 離線
    • 藥局
    • 獸醫醫院和診所
  • 網路藥房

第14章：獸藥市場：依治療領域分類

  • 抗感染藥物
  • 行為障礙
  • 循環系統
  • 皮膚科
  • 內分泌學
  • 消化系統疾病
  • 營養支持
  • 腫瘤學
  • 疼痛管理

第15章：獸藥市場：依最終用戶分類

  • 動物收容所和救援組織
  • 畜牧業承諾
  • 寵物飼主
  • 獸醫
  • 動物園和水族館

第16章：獸藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章：獸藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 獸藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國獸藥市場

第20章：中國獸藥市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Akina Animal Health
  • Aurora Compounding Pharmacy INC
  • Caringbah Compounding Pharmacy
  • Central Compounding Center South
  • Chiron Compounding Pharmacy, Inc
  • Custom-Med Compounding Pharmacy
  • Davis Islands Pharmacy
  • Dougherty's Pharmacy, Inc
  • Hoye's Pharmacy
  • Medisca Inc.
  • MEDS Canadian Compounding Pharmacy
  • Millers Pharmacy
  • Pace Pharmacy
  • People's Choice of Pharmacy
  • Pratt's Compounding Pharmacy
  • Sixth Avenue Medical Pharmacy
  • Smith Caldwell Drug Store by Walgreen Co.
  • Specialist Compounding Pharmacy Pte Ltd
  • Tache Pharmacy & Medical Supplies
  • Triangle Compounding Pharmacy
  • Vertisis Custom Pharmacy
  • Victoria Compounding Pharmacy
  • Vimian Group AB
  • Wedgewood Pharmacy
  • Wellness Pharmacy of Cary
Product Code: MRR-3204321AF708

The Animal Drug Compounding Market was valued at USD 1.45 billion in 2025 and is projected to grow to USD 1.57 billion in 2026, with a CAGR of 8.10%, reaching USD 2.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.45 billion
Estimated Year [2026] USD 1.57 billion
Forecast Year [2032] USD 2.51 billion
CAGR (%) 8.10%

An authoritative framing of the strategic role, scope, and practical objectives of animal drug compounding for veterinary practice and agricultural health

This executive summary begins by framing the strategic imperative of animal drug compounding in contemporary veterinary practice and agricultural management. Compounding extends the therapeutic toolbox available to veterinarians and animal health professionals by enabling dose customization, alternative formulations for small or sensitive species, and tailored combinations where approved products are not available. As a result, compounding supports clinical outcomes across acute and chronic indications, enhances medication adherence in companion animals, and provides targeted solutions for specialized livestock interventions.

The introduction clarifies the scope of inquiry, encompassing product classes, administration routes, formulation types, compounding modalities, distribution pathways, therapeutic areas and primary end users. It also situates the analysis within current regulatory expectations, quality assurance imperatives, and evolving supply chain pressures. Throughout this report, emphasis is placed on practical relevance: insights are oriented toward operational leaders, veterinary practitioners, formulary decision-makers and channel partners seeking to optimize clinical utility while maintaining compliance with sterility and safety standards.

Finally, the introduction outlines research objectives including profiling clinical demand drivers, mapping critical operational constraints, and identifying strategic priorities for stakeholders committed to improving therapeutic availability and safety for both companion and production animals. The aim is to translate technical analysis into actionable pathways for implementation and risk mitigation across compounding workflows.

How tightening regulation, supply chain volatility, and clinical demand for customized therapies are reshaping compounding operations and quality systems

Over recent years the landscape of animal drug compounding has been reshaped by several transformative shifts that touch regulation, clinical practice, and supply chain dynamics. Regulatory frameworks have tightened global expectations around sterility, labeling and batch documentation, prompting compounding operations to invest in enhanced quality systems and environmental monitoring programs. Meanwhile, clinical practice has evolved as veterinarians increasingly rely on customized formulations to manage chronic conditions, geriatric care, and species-specific dosing challenges that commercially available products do not address.

Technological diffusion has introduced more sophisticated formulation tools, automated dispensing, and digital recordkeeping that both improve traceability and create new compliance baselines. Concurrently, supply chain volatility - from API sourcing to packaging components - has encouraged compounding providers to diversify suppliers, strengthen inventory controls and pursue localized sourcing strategies where feasible. Patient- and owner-centric trends, such as demand for palatable oral solutions for cats and novel topical modalities for dermatologic conditions, have driven formulation innovation and closer collaboration between compounding pharmacists and clinicians.

Collectively, these shifts demand integrated responses: investments in sterile-processing infrastructure where injectable formulations are required, cross-functional protocols that bridge clinical needs with manufacturing capability, and quality frameworks that balance agility with robust risk controls. In short, the environment now rewards operators who can combine technical excellence with adaptive supply chain and client-centered service models.

Operational and procurement implications of U.S. tariff adjustments in 2025 on sourcing, formulation validation, and pricing dynamics across compounding operations

Tariff policies and trade measures enacted or adjusted in the United States during 2025 have a material operational impact on the compounding ecosystem, particularly where active pharmaceutical ingredients, excipients, packaging materials and specialized equipment are imported. Increased tariff burdens on specific chemical classes or finished components add cost pressure to inputs that are often sourced globally, prompting procurement teams to reassess supplier portfolios and total landed cost calculations. These effects are amplified for smaller compounding pharmacies and clinics that lack scale to absorb sudden input-price volatility.

As a consequence, many stakeholders are pivoting toward greater supplier diversification and contract renegotiation to secure more predictable access to critical materials. Some compounding operations are exploring local sourcing for certain excipients and primary packaging, while others are accelerating investments in inventory buffering and demand forecasting to mitigate the timing impact of tariff-driven lead-time changes. Regulatory compliance intersects with these adjustments because substitutions, even for non-active components, may require validation or notification depending on jurisdictional rules, which in turn influences operational agility.

In parallel, tariff-related cost shifts are nudging pricing conversations with payers and animal owners, as well as prompting greater scrutiny on formulation rationales to ensure that compounded alternatives demonstrate clear clinical necessity. For industry leaders, the tariff environment underscores the importance of integrated procurement strategies, transparent supplier qualification processes, and robust scenario planning that aligns sourcing decisions with quality and clinical imperatives.

A detailed segmentation framework connecting drug classes, species-specific needs, formulation types, administration routes, distribution channels and end-user profiles to operational priorities

A granular segmentation lens reveals where clinical need, formulation capability, and distribution overlap to create targeted opportunities and operational challenges. Based on drug type, compounding demand spans Anti-infective Agents, Anti-inflammatory Agents, CNS Agents, and Hormones & Substitutes, each of which presents distinct stability, excipient and sterility considerations. For example, hormonal preparations may require specialized handling and cold-chain awareness, while CNS agents often entail precise dose titration and careful monitoring for adverse effects.

Based on animal type, the patient pool divides into Companion Animals and Livestock. Companion Animals are further stratified into Cats, Dogs, and Horses, and each species drives unique palatability and administration preferences that influence formulation selection. Livestock further subdivides into Cattle, Poultry, Sheep & Goats, and Swine, where mass-dosing logistics, withdrawal periods and residue testing become paramount considerations for compounding strategies. Based on form, common formats include Capsules, Solutions, and Suspensions, and the choice of form affects adherence, dosing accuracy and stability profiles.

Based on route of administration, Injectable, Oral, and Topical pathways demand different sterility controls, packaging and administration training for end users. Based on compounding type, operations distinguish between Non-Sterile Compounding and Sterile Compounding, driving divergent infrastructure needs, from laminar-flow hoods to validated cleanroom suites. Based on distribution channel, the ecosystem includes Offline and Online Pharmacies, with Offline further segmented into Compounding Pharmacies and Veterinary Hospitals & Clinics; these channels influence turnaround time expectations, client interaction models and returns management. Based on therapeutic area, compounding addresses Anti-Infectives, Behavioral Disorders, Cardiology, Dermatology, Endocrinology, Gastrointestinal Disorders, Nutritional Support, Oncology, and Pain Management, each requiring tailored clinical protocols. Finally, based on end user, primary recipients include Animal Shelters & Rescues, Livestock Farmers, Pet Owners, Veterinarians, and Zoological Institutions, and each end user profile shapes procurement rhythm, formulation preferences and documentation needs.

This segmentation-driven perspective clarifies where investment in specific capabilities-such as sterile processing for injectable oncology adjuncts, palatable suspension development for feline patients, or scalable oral solutions for herd treatment-will deliver the greatest clinical and commercial return. It also highlights the importance of aligning quality management, supply continuity, and distribution models to the specific demands of each segment.

How regional regulatory diversity, supply chain roles, and adoption patterns in the Americas, EMEA and Asia-Pacific shape compounding strategies and operational risk

Regional dynamics continue to define regulatory expectations, sourcing strategies and adoption patterns across the compounding landscape. In the Americas, regulatory frameworks emphasize traceability, sterility assurance and transparency of compounding records, while commercial adoption is shaped by a dense ecosystem of veterinary clinics and specialty compounding pharmacies that serve both companion animals and large farming operations. This regional configuration supports rapid clinical feedback loops but also concentrates regulatory scrutiny on compounding practices and documentation.

In Europe, Middle East & Africa, heterogeneous regulatory environments require nuanced compliance strategies and localized quality controls, with some markets imposing stringent pharmacopoeial adherence and others prioritizing access in veterinary public health contexts. Distribution modalities in this macro-region vary widely, and cross-border supply chains often necessitate harmonized labeling and stability data that satisfy multiple jurisdictions. Asia-Pacific exhibits dynamic demand drivers, with rapid growth in companion animal ownership in urban centers and continuing modernization of livestock practices. The region also plays a meaningful role in the global supply chain for APIs and primary packaging, which creates both opportunity and exposure to upstream manufacturing variation.

Across all regions, differences in veterinary infrastructure, cold-chain capabilities, and professional training affect the feasibility of certain compounded therapies. Consequently, regional strategies must reconcile local regulatory requirements, supply chain realities and clinical practice norms to ensure that compounding services remain safe, accessible and operationally sustainable.

Strategic priorities and operational differentiators among compounding providers focused on quality infrastructure, clinical integration, and resilient supply chains

Companies operating in the animal drug compounding space are converging around several strategic imperatives that differentiate performance and resilience. Leading compounding pharmacies and service providers are prioritizing quality infrastructure investments, including validated cleanrooms, environmental monitoring systems and rigorous sterility testing protocols, to meet heightened regulatory expectations and to enable growth into injectable and biologic-adjacent formulations. Parallel to facility upgrades, firms are formalizing compliance programs with standardized batch records, electronic traceability and routine third-party audits.

Commercially, innovators are developing integrated service models that combine rapid-turnaround compounding with clinical consultation, training for administration by veterinarians or farm personnel, and digital platforms for prescription management. Partnerships between compounding producers and veterinary hospital networks enable tighter clinical feedback loops, accelerating iterative improvements in palatability, dosing accuracy and ease of administration. On the supply side, companies are investing in supplier qualification processes, dual-sourcing arrangements for critical APIs and localized inventories to reduce exposure to international logistical disruptions.

Additionally, some organizations are pursuing research collaborations to validate stability profiles and to expand the evidence base for compounded therapies in specific species and therapeutic contexts. Talent and capability building-across sterile processing technicians, veterinary pharmacists and regulatory specialists-remains a key differentiator. Collectively, these company-level strategies reveal a competitive landscape where compliance excellence, clinical integration and supply chain agility determine sustainable value creation.

Practical, high-impact operational, procurement, clinical collaboration, and quality actions for compounding leaders to strengthen safety and business continuity

Industry leaders should adopt a set of pragmatic, high-impact actions to safeguard patient safety, regulatory compliance and commercial continuity across compounding operations. First, prioritize investments in validated aseptic processing and environmental monitoring that align with current pharmacopeial expectations; this reduces risk exposure for injectable formulations and supports expanded clinical offerings. Next, implement comprehensive supplier qualification protocols, including dual-source strategies for critical APIs and periodic supplier audits, to mitigate tariff and supply chain volatility.

Simultaneously, strengthen clinical collaboration by formalizing feedback mechanisms with veterinarians and end users to refine palatability, dosing formats and administration training. Design digital prescription and fulfillment workflows that increase traceability while also improving turnaround times for practitioners. Where feasible, standardize stability and validation studies for frequently compounded formulations to limit ad hoc substitutions and to improve consistency across batches. Complement technical measures with workforce development programs that elevate competence in sterile technique, compounding documentation and regulatory reporting.

Finally, incorporate scenario-based procurement planning that explicitly models tariff and logistics contingencies, and develop transparent pricing rationales that can be communicated to clients when input costs fluctuate. Taken together, these steps create a defensible operational posture that balances clinical responsiveness with robust quality controls and commercial transparency.

A transparent mixed-methods research approach combining practitioner interviews, site assessments, regulatory review and data triangulation to ensure practical and verifiable insights

The research underpinning this report used a mixed-methods approach to ensure comprehensive, verifiable insights into compounding operations, regulatory context, and end-user behavior. Primary research included structured interviews with practicing veterinarians, compounding pharmacists, quality assurance professionals and supply chain managers to capture real-world operational constraints and clinical priorities. In addition, site assessments and process observations provided direct visibility into facility layout, sterile processing controls and documentation practices.

Secondary research involved systematic review of regulatory guidance, pharmacopeial standards, and publicly available clinical literature to validate technical assertions on stability, sterility and therapeutic rationale for compounded preparations. Data triangulation combined qualitative inputs with operational indicators from industry reports, procurement trends and supplier intelligence to produce robust thematic conclusions. Analytical frameworks included segmentation analysis across drug type, animal species, formulation, route of administration, compounding modality, distribution channel, therapeutic area and end-user cohort.

Limitations of the methodology are acknowledged; availability of proprietary operational metrics varied across respondents, and regulatory interpretations differ by jurisdiction which may affect local implementation. Where differences emerged, the analysis highlights variance and suggests decision points for stakeholders. Overall, the methodology emphasizes reproducibility, transparency and practical relevance for clinical and commercial leaders.

Synthesis of strategic imperatives emphasizing quality, clinical collaboration, procurement resilience and regionally adapted approaches for sustainable compounding operations

This executive summary synthesizes core imperatives for the animal drug compounding sector: maintain uncompromising quality systems, align formulation capabilities with species- and therapy-specific needs, and build resilient supply chains that can absorb tariff and logistics disruption. Operational preparedness in sterile processing and documentation is essential to broaden the range of safe injectable and complex formulations. Meanwhile, clinical collaboration and feedback loops with veterinarians and end users remain central to achieving therapeutic efficacy and adherence, particularly for companion animals with heightened palatability and dosing challenges.

Procurement strategies that emphasize supplier qualification, inventory stewardship and scenario planning provide a pragmatic buffer against input volatility. Regionally differentiated approaches are necessary because regulatory frameworks, vet infrastructure, and supply chain roles vary significantly across the Americas, EMEA and Asia-Pacific. Companies that integrate technical excellence with flexible commercial models and targeted workforce development will be best positioned to deliver clinically meaningful compounded therapies while meeting evolving compliance expectations.

In closing, sustained focus on quality, clinical integration and supply chain intelligence will enable compounding operations to respond responsibly to both everyday veterinary needs and emergent therapeutic demands, preserving patient safety and supporting long-term operational viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Drug Compounding Market, by Drug Type

  • 8.1. Anti-infective Agents
  • 8.2. Anti-inflammatory Agents
  • 8.3. CNS Agents
  • 8.4. Hormones & Substitutes

9. Animal Drug Compounding Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
    • 9.1.3. Horses
  • 9.2. Livestock
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep & Goats
    • 9.2.4. Swine

10. Animal Drug Compounding Market, by Form

  • 10.1. Capsules
  • 10.2. Solutions
  • 10.3. Suspensions

11. Animal Drug Compounding Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
  • 11.3. Topical

12. Animal Drug Compounding Market, by Compounding Type

  • 12.1. Non-Sterile Compounding
  • 12.2. Sterile Compounding

13. Animal Drug Compounding Market, by Distribution Channel

  • 13.1. Offline
    • 13.1.1. Compounding Pharmacies
    • 13.1.2. Veterinary Hospitals & Clinics
  • 13.2. Online Pharmacies

14. Animal Drug Compounding Market, by Therapeutic Area

  • 14.1. Anti-Infectives
  • 14.2. Behavioral Disorders
  • 14.3. Cardiology
  • 14.4. Dermatology
  • 14.5. Endocrinolog
  • 14.6. Gastrointestinal Disorders
  • 14.7. Nutritional Support
  • 14.8. Oncology
  • 14.9. Pain Management

15. Animal Drug Compounding Market, by End User

  • 15.1. Animal Shelters & Rescues
  • 15.2. Livestock Farmers
  • 15.3. Pet Owners
  • 15.4. Veterinarians
  • 15.5. Zoological Institutions

16. Animal Drug Compounding Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Animal Drug Compounding Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Animal Drug Compounding Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Animal Drug Compounding Market

20. China Animal Drug Compounding Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Akina Animal Health
  • 21.6. Aurora Compounding Pharmacy INC
  • 21.7. Caringbah Compounding Pharmacy
  • 21.8. Central Compounding Center South
  • 21.9. Chiron Compounding Pharmacy, Inc
  • 21.10. Custom-Med Compounding Pharmacy
  • 21.11. Davis Islands Pharmacy
  • 21.12. Dougherty's Pharmacy, Inc
  • 21.13. Hoye's Pharmacy
  • 21.14. Medisca Inc.
  • 21.15. MEDS Canadian Compounding Pharmacy
  • 21.16. Millers Pharmacy
  • 21.17. Pace Pharmacy
  • 21.18. People's Choice of Pharmacy
  • 21.19. Pratt's Compounding Pharmacy
  • 21.20. Sixth Avenue Medical Pharmacy
  • 21.21. Smith Caldwell Drug Store by Walgreen Co.
  • 21.22. Specialist Compounding Pharmacy Pte Ltd
  • 21.23. Tache Pharmacy & Medical Supplies
  • 21.24. Triangle Compounding Pharmacy
  • 21.25. Vertisis Custom Pharmacy
  • 21.26. Victoria Compounding Pharmacy
  • 21.27. Vimian Group AB
  • 21.28. Wedgewood Pharmacy
  • 21.29. Wellness Pharmacy of Cary

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL DRUG COMPOUNDING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CNS AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CNS AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CNS AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORMONES & SUBSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORMONES & SUBSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORMONES & SUBSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NON-STERILE COMPOUNDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NON-STERILE COMPOUNDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NON-STERILE COMPOUNDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY STERILE COMPOUNDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY STERILE COMPOUNDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY STERILE COMPOUNDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY BEHAVIORAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY BEHAVIORAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY BEHAVIORAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ENDOCRINOLOG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ENDOCRINOLOG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ENDOCRINOLOG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL SHELTERS & RESCUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL SHELTERS & RESCUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL SHELTERS & RESCUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK FARMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK FARMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK FARMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARIANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARIANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY VETERINARIANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ZOOLOGICAL INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ZOOLOGICAL INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ZOOLOGICAL INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 245. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 246. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 250. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 251. GCC ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 281. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 282. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 283. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 287. G7 ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 293. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 294. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 299. NATO ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES ANIMAL DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA ANIMAL DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA ANIMAL DRU